Avenir Wellness Solutions Inc (AVRW)

[myearnings]

CURES Canopy Growth related revenues will be minimal royalties for the next 2 to 3 years. CURE exclusively licensed rights to manufacturing Cure's product via their agreement in 2018. There will be some royalties payments in 2020 but much as. The CURE Canopy agreement lacks any real revenue projections and projects zero manufacturing by CURE since Canopy Growth licensed that right. See the link below:

https://content.edgar-online.com/ExternalLink/EDGAR/0001477932-18-004377.html?hash=b15a1917f6512ec9264e8ad9e0b42b7406de011f948315172cd75b9f367b4781&dest=CURR_EX991_HTM#CURR_EX991_HTM

The announcement looked nice for the market but as CURE's trend shows the manufacturing and projection of revenues is not there. Where are the "real" projections and confidence? Keep in mind CURE's operational accumulated debt.

CURE's strategic approach and route to market on all three products SLEEP, Vitamin D3 and Cure Cana (not ready yet) are exclusively licensed for multiple years to single entities with no manufacturing by CURE. This begs many question and how does Cure expect to produce real revenue growth with this approach? Keep in mind, Canopy Growth will not be manufacturing any of this in the USA.

The recent agreement with Moreoven, LLC (florida entity) for Vitamin D3 was just signed in May of this year ( A 5 year exclusive) with zero projections. FYI, Moreoven, LLC has a network but is not considered a significant supplier of vitamins in the USA. Why not look to manufacture it now (China being the largest supplier approximately 80%+ of the market now is under under tariff attacks). Remember the USA is the biggest human consumer. There are 4 or 5 easy targets other than Moreoven if CURE wished to Partner with greater suppliers.

So, with these strategic approaches being executed investors should be questioning the confidence of the leadership to show real revenue projections. Cure has reasonable IP but the leadership is not exploiting strategic revenue growth.